ResMed's Patent Victory Boosts Share Price Amidst Legal Triumph

2 min read | December 12, 2023 05:43 PM AEDT | By Team Kalkine Media

Google News:

ResMed's Patent Victory Boosts Share Price Amidst Legal Triumph — Image source: © Rafaelhenriquepress | Megapixl.com

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

ResMed, a prominent figure in healthcare, boasts a considerable portfolio of more than 9,500 issued or pending patents and designs. The ASX 200 healthcare share has experienced a surge in its share price, notably today, with shares valued at AU$25.06 apiece, marking a 1.25% increase from yesterday's closing price of AU$24.75.

Impact of Legal Victory on ResMed

This rise in share value follows a significant legal triumph for ResMed against New York University (NYU). The United States Patent Trial and Appeals Board ruled in favor of ResMed, dismissing patent infringement claims filed by NYU in June 2021.

Analysis of Patent Claims

NYU's claims revolved around alleged patent infringement concerning ResMed's AutoSetTM and AutoRampTM features in its AirSenseTM 10 AutoSet flow generators. However, the US Patent Trial judges found all challenged claims across the seven patents invalid, supporting ResMed's defense of its technology.

Statements from ResMed's Representatives

Michael Rider, ResMed's global general counsel and secretary, expressed satisfaction in defending their innovations vigorously. He emphasized the company's dedication to research, development, and patent protection to safeguard their inventions.

ResMed's CEO, Mick Farrell, highlighted the company's long-term investment in R&D, resulting in an extensive patent portfolio. Farrell emphasized ResMed's commitment to defending its innovations to ensure better patient therapy solutions.

ResMed's Share Price Performance

In 2023, the ResMed share price witnessed an 17.70% decline; however, recent movements indicate a positive trend with an 12.08% increase in the past month.

Conclusion

ResMed's legal triumph against NYU serves as a testament to its commitment to innovation and dedication to protecting its technology through patent rights. The recent positive share price movements showcase renewed investor confidence in the company's resilience and innovative prowess.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.